Callyaerin A

General Information


DRACP ID  DRACP00560

Peptide Name   Callyaerin A

Sequence  IXVILPPLXPIFG

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Callyspongia aerizusa

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
THP-1 Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia Leukemia IC50=30µM; IC90=50µM Resazurin assay 48h 1
L5178Y Mouse leukemia Leukemia ED50=3.61µM MTT assay 72h 2

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  MRC-5:IC50=20µM; IC90=40µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  SMB: Ile1<--->X(9)

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  X(2)= 4-Hydroxyproline; X(9)=Daa

Chiral  L



Physicochemical Information


Formula  C61H95N11O10

Absent amino acids  ACDEHKMNQRSTWY

Common amino acids  IP

Mass  157672

Pl  6.11

Basic residues  0

Acidic residues  0

Hydrophobic residues  7

Net charge  0

Boman Index  3256

Hydrophobicity  176.15

Aliphatic Index  172.31

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 26213786

Title  Callyaerins from the Marine Sponge Callyspongia aerizusa: Cyclic Peptides with Antitubercular Activity

Doi 10.1021/acs.jnatprod.5b00266

Year  2015

Literature 2

Pubmed ID 20599387

Title  Callyaerins A-F and H, new cytotoxic cyclic peptides from the Indonesian marine sponge Callyspongia aerizusa

Doi 10.1016/j.bmc.2010.06.012

Year  2010

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.